UBS Group
THNR

UBS Group’s Amplify Weight Loss Drug & Treatment ETF THNR Stock Holding History

UBS Group’s Portfolio THNR Stock Details THNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.75K Buy
+193
New +$4.92K ﹤0.01% 8892
2025
Q4 		– Sell
-2,184
Closed -$51.1K – 11333
2025
Q3 		$51.1K Sell
2,184
-369
-14% -$8.48K ﹤0.01% 7546
2025
Q2 		$58K Buy
2,553
+1,955
+327% +$42.4K ﹤0.01% 7659
2025
Q1 		$12.9K Buy
598
+152
+34% +$3.46K ﹤0.01% 8477
2024
Q4 		$10.1K Buy
446
+224
+101% +$5.53K ﹤0.01% 8323
2024
Q3 		$5.95K Buy
+222
New +$5.96K ﹤0.01% 8013

Other funds holding THNR

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
GFA
Godfrey Financial Associates Glenmont, New York $117M AUM

UBS Group's THNR Position: Q1 2026 in Review

UBS Group opened a new position in Amplify Weight Loss Drug & Treatment ETF (THNR) in Q1 2026: 193 shares worth $4.75K. The stake represents ﹤0.01% of the portfolio and ranks #8892 among its holdings. This is a return to the name: UBS Group previously reported a position in THNR as recently as Q3 2025.

UBS Group first reported a position in THNR in Q3 2024 and has held it in 6 quarters since. The position peaked at $58K in Q2 2025. 4 funds tracked by Wall St. Rank hold THNR as of Q1 2026.

  • UBS Group held 193 shares of Amplify Weight Loss Drug & Treatment ETF worth $4.75K as of Q1 2026.
  • Amplify Weight Loss Drug & Treatment ETF was a new UBS Group position in Q1 2026.
  • Amplify Weight Loss Drug & Treatment ETF made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8892 holding.
  • UBS Group first reported a position in Amplify Weight Loss Drug & Treatment ETF in Q3 2024 and has held it in 6 quarters since.
  • UBS Group's Amplify Weight Loss Drug & Treatment ETF position peaked at $58K in Q2 2025.
  • 4 funds tracked by Wall St. Rank held Amplify Weight Loss Drug & Treatment ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.